Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (13857)	1/29/1998 10:44:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

> LGNd is now getting hit. Down 7/16th Possibly due to that 'nightline' rumor. I seem to recall that the NYTimes article stated that AMLN was 'closest' to market. This may be perceived as a negative for LGND. OFF TOPIC - Looks like DELL will hit $100 today and MSFT $150. --Tony

To: Hippieslayer who wrote (13857)	1/29/1998 11:56:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI, Just to clarify on the NY Times article, AMLN was discussed when the article focused on Type I and the "closer" to market was relative to various exotic approaches for type I. Most of the article was on type II which is a much bigger market, and that portion of the article focused on oral treatment where Ligand (Targretin) and Lilly were discussed in some detail. Here's the intro to type I and ANLM's "closer to market" approach: Patients with Type 1 diabetes, once commonly known as juvenile diabetes, must take multiple insulin shots every day to survive. About 750,000 people in the United States have Type 1 diabetes, a disease in which the body mistakenly destroys the beta cells in the pancreas that produce insulin. There are no oral therapies for Type 1 diabetes. Partly because it affects fewer patients, and partly because it is largely controlled by insulin, Type 1 diabetes has attracted fewer companies. But several are working on encapsulated pancreas cells from animal or human donors, in hopes of eliminating the daily injections by creating a sustainable source of insulin that could evade the immune system. Others are trying to develop genetically engineered animals that could serve as pancreas donors. Both efforts are a long way from fruition. Closer to market, Amylin Pharmaceuticals Inc. of La Jolla, Calif., was formed in 1987 to develop a genetically engineered version of the hormone amylin, which is normally produced in the same pancreas cells as insulin. Type 1 diabetics do not produce amylin on their own, either.